PD-1/PD-L1-IN-24

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PD-1/PD-L1-IN-24 

PD-1/PD-L1-IN-24 是一种高效的 PD-1/PD-L1 抑制剂，IC50 为 1.57 nM。PD-1/PD-L1-IN-24 通过提高 IFN-γ 来在细胞水平上恢复 T 细胞功能。PD-1/PD-L1-IN-24 对 PBMCs 具有较低的细胞毒性。

PD-1/PD-L1-IN-24

PD-1/PD-L1-IN-24 Chemical Structure

CAS No. : 2667680-33-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PD-1/PD-L1-IN-24 is a highly potent PD-1/PD-L1 inhibitor with IC50 value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs[1].

IC50 & Target

IC50: 1.57 nM (PD-1/PD-L1)[1]
体外研究
(In Vitro)

PD-1/PD-L1-IN-24 (compound 39) (0-10 μM; 6 hours) significantly releases PD-L1-mediated inhibition of PD-1-expressing Jurkat T cells at the concentration of 10 μM[1].
PD-1/PD-L1-IN-24 (0.003-20 μM; 72 hours) exhibits no significant toxicity at concentrations ranging from 0.003 to 2.22 μM, and the IC50 is 12.42 μM[1].
PD-1/PD-L1-IN-24 (0.082, 0.247, 0.741 and 2.222 μM; 72 hours) significantly elevates the secretion of IFN-γ with a dose-dependent manner in T cell-tumor co-culture cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line: PBMC[1]
Concentration: 0.003, 0.0091, 0.027, 0.082, 0.247, 0.741, 2.222, 6.67 and 20 μM
Incubation Time: 72 hours
Result: No significant toxicity was observed at concentrations ranging from 0.003 to 2.22 μM, and the IC50 was 12.42 μM.

分子量

640.08

Formula

C34H30ClN5O6
CAS 号

2667680-33-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wang Y, Kun Huang, Gao Y, et al. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction. Eur J Med Chem. 2022;229:113998.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务